Clinical Trial Update: Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies [NA]

View source ↗

Summary

This clinical trial compares reduced-dose apixaban and rivaroxaban against low-molecular-weight heparin for venous thromboembolism management in patients with h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Leukemia
• Lymphoma
• Multiple Myeloma

Drugs mentioned

• Apixaban (Eliquis) (apixaban)
• Low molecular weight heparin (low molecular weight heparin)
• Rivaroxaban (Xarelto) (rivaroxaban)

Snippet

Sponsor: Medical University of Gdansk | Conditions: Lymphoma, Leukemia | NA | Status: RECRUITING